In this issue:
- Transmitted resistance to NRTIs and virological failure risk in integrase inhibitor recipients
- Effectiveness of HIV PrEP among MSM/transgender with bacterial STIs
- Outcomes for late HIV presenters starting integrase inhibitors vs. PIs
- Preferences for future HIV PrEP products among MSM
- TAF vs. TDF: updated meta-analysis
- Low use of condom and high STI incidence among MSM receiving PrEP
- Single-tablet darunavir/ cobicistat/emtricitabine/TAF for HIV-1 infection
- Repeated syphilis episodes in HIV-infected MSM
- Switching from etravirine/ raltegravir twice to once daily
- HIV self vs. standard testing for key populations
Please login below to download this issue (PDF)